{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T17:01:43Z","timestamp":1790096503752,"version":"4.0.1"},"reference-count":138,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T00:00:00Z","timestamp":1589932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Alzheimer\u2019s disease (AD) is a complex neurodegenerative disease that requires extremely specific biomarkers for its diagnosis. For current diagnostics capable of identifying AD, the development and validation of early stage biomarkers is a top research priority. Body-fluid biomarkers might closely reflect synaptic dysfunction in the brain and, thereby, could contribute to improving diagnostic accuracy and monitoring disease progression, and serve as markers for assessing the response to disease-modifying therapies at early onset. Here, we highlight current advances in the research on the capabilities of body-fluid biomarkers and their role in AD pathology. Then, we describe and discuss current applications of the potential biomarkers in clinical diagnostics in AD.<\/jats:p>","DOI":"10.3390\/diagnostics10050326","type":"journal-article","created":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T10:37:38Z","timestamp":1589971058000},"page":"326","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Role of Body-Fluid Biomarkers in Alzheimer\u2019s Disease Diagnosis"],"prefix":"10.3390","volume":"10","author":[{"given":"Thuy Trang","family":"Nguyen","sequence":"first","affiliation":[{"name":"Faculty of Pharmacy, Ho Chi Minh City University of Technology (HUTECH), Ho Chi Minh City 700000, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qui Thanh Hoai","family":"Ta","sequence":"additional","affiliation":[{"name":"Institute of Research and Development, Duy Tan University, Danang 550000, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thi Kim Oanh","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Faculty of Food Science and Technology, Ho Chi Minh City University of Food Industry, Ho Chi Minh City 700000, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thi Thuy Dung","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Faculty of Environmental and Food Engineering, Nguyen Tat Thanh University, Ho Chi Minh City 70000, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9937-7865","authenticated-orcid":false,"given":"Van Giau","family":"Vo","sequence":"additional","affiliation":[{"name":"Department of Industrial and Environmental Engineering, Graduate School of Environment, Gachon University, 1342 Sungnam-daero, Sujung-gu, Seongnam-si, Gyeonggi-do 461-701, Korea"},{"name":"Department of BionanoTechnology, Gachon University, 1342 Sungnam-daero, Sujung-gu, Seongnam-si, Gyeonggi-do 461-701, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,5,20]]},"reference":[{"key":"ref_1","first-page":"108","article-title":"The Role of Genetics in Advancing Precision Medicine for Alzheimer\u2019s Disease-A Narrative Review","volume":"5","author":"Li","year":"2018","journal-title":"Front. Med. (Lausanne)"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1016\/S0140-6736(17)31363-6","article-title":"Dementia prevention, intervention, and care","volume":"390","author":"Livingston","year":"2017","journal-title":"Lancet (London, England)"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S0140-6736(14)61347-7","article-title":"The burden of disease in older people and implications for health policy and practice","volume":"385","author":"Prince","year":"2015","journal-title":"Lancet (London, England)"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s13273-018-0015-3","article-title":"Clinical genetic strategies for early onset neurodegenerative diseases","volume":"14","author":"Giau","year":"2018","journal-title":"Mol. Cell. Toxicol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s13273-015-0011-9","article-title":"Gene panels and primers for next generation sequencing studies on neurodegenerative disorders","volume":"11","author":"An","year":"2015","journal-title":"Mol. Cell. Toxicol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Pais, M., Martinez, L., Ribeiro, O., Loureiro, J., Fernandez, R., Valiengo, L., Canineu, P., Stella, F., Talib, L., and Radanovic, M. (2020). Early diagnosis and treatment of Alzheimer s disease: New definitions and challenges. Braz. J. Psychiatry.","DOI":"10.1590\/1516-4446-2019-0735"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/msj.20157","article-title":"Neuropathology of Alzheimer\u2019s disease","volume":"77","author":"Perl","year":"2010","journal-title":"Mt. Sinai J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000369101","article-title":"Amyloid-Beta: A Crucial Factor in Alzheimer\u2019s Disease","volume":"24","author":"Sabermarouf","year":"2015","journal-title":"Med Princ. Pract."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/aps.2017.28","article-title":"Amyloid beta: Structure, biology and structure-based therapeutic development","volume":"38","author":"Chen","year":"2017","journal-title":"Acta Pharmacol. Sinica"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research Framework: Toward a biological definition of Alzheimer\u2019s disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimer\u2019s Dement. J. Alzheimer\u2019s Assoc."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/s41591-020-0797-4","article-title":"Another step forward in blood-based diagnostics for Alzheimer\u2019s disease","volume":"26","author":"Bateman","year":"2020","journal-title":"Nat. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jalz.2013.01.013","article-title":"The future of blood-based biomarkers for Alzheimer\u2019s disease","volume":"10","author":"Henriksen","year":"2014","journal-title":"Alzheimer\u2019s Dement. J. Alzheimer\u2019s Assoc."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1159\/000448394","article-title":"Electroencephalography Is a Good Complement to Currently Established Dementia Biomarkers","volume":"42","author":"Ferreira","year":"2016","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.metabol.2014.10.034","article-title":"Biomarkers in the diagnosis and management of Alzheimer\u2019s disease","volume":"64","author":"Wurtman","year":"2015","journal-title":"Metab. Clin. Exp."},{"key":"ref_15","first-page":"291","article-title":"In vivo Detection of Alzheimer\u2019s Disease","volume":"91","author":"Leuzy","year":"2018","journal-title":"Yale J. Biol. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"E42","DOI":"10.3390\/diagnostics7030042","article-title":"Cerebrospinal Fluid Biomarkers in Alzheimer\u2019s Disease-From Brain Starch to Bench and Bedside","volume":"7","author":"Pawlowski","year":"2017","journal-title":"Diagnostics"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/B978-0-12-804279-3.00006-X","article-title":"Cerebrospinal fluid in the dementias","volume":"146","author":"Zetterberg","year":"2017","journal-title":"Handb. Clin. Neurol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jneumeth.2018.10.025","article-title":"Blood-based biomarkers for Alzheimer\u2019s disease-An update","volume":"319","author":"Zetterberg","year":"2019","journal-title":"J. Neurosci. Methods"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/S1474-4422(10)70223-4","article-title":"Revising the definition of Alzheimer\u2019s disease: A new lexicon","volume":"9","author":"Dubois","year":"2010","journal-title":"Lancet Neurol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/nm1782","article-title":"Amyloid-beta protein dimers isolated directly from Alzheimer\u2019s brains impair synaptic plasticity and memory","volume":"14","author":"Shankar","year":"2008","journal-title":"Nat. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1523\/JNEUROSCI.3501-06.2007","article-title":"Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer\u2019s disease","volume":"27","author":"Lacor","year":"2007","journal-title":"J. Neurosci. Off. J. Soc. Neurosci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"11947","DOI":"10.1523\/JNEUROSCI.2009-17.2017","article-title":"Human Brain-Derived Abeta Oligomers Bind to Synapses and Disrupt Synaptic Activity in a Manner That Requires APP","volume":"37","author":"Wang","year":"2017","journal-title":"J. Neurosci. Off. J. Soc. Neurosci."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.mcn.2007.02.006","article-title":"Rapid, concurrent alterations in pre- and postsynaptic structure induced by naturally-secreted amyloid-beta protein","volume":"35","author":"Calabrese","year":"2007","journal-title":"Mol. Cell. Neurosci."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1093\/brain\/aws127","article-title":"Apolipoprotein E4 effects in Alzheimer\u2019s disease are mediated by synaptotoxic oligomeric amyloid-beta","volume":"135","author":"Koffie","year":"2012","journal-title":"Brain A J. Neurol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S0002-9440(10)65184-X","article-title":"Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer\u2019s disease","volume":"155","author":"Lue","year":"1999","journal-title":"Am. J. Pathol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13195-020-00588-4","article-title":"The Synaptic Health Endpoints Working, The clinical promise of biomarkers of synapse damage or loss in Alzheimer\u2019s disease","volume":"12","author":"Zetterberg","year":"2020","journal-title":"Alzheimers Res. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1001\/archneurol.2008.596","article-title":"Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain","volume":"66","author":"Tapiola","year":"2009","journal-title":"Arch. Neurol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1001\/archneur.58.3.373","article-title":"Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice","volume":"58","author":"Andreasen","year":"2001","journal-title":"Arch. Neurol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.neulet.2007.03.064","article-title":"Longitudinal stability of CSF biomarkers in Alzheimer\u2019s disease","volume":"419","author":"Blennow","year":"2007","journal-title":"Neurosci. Lett."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"767","DOI":"10.3233\/JAD-2012-120019","article-title":"Longitudinal cerebrospinal fluid biomarkers over four years in mild cognitive impairment","volume":"30","author":"Mattsson","year":"2012","journal-title":"J. Alzheimer\u2019s Dis. JAD"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3233\/JAD-2007-12307","article-title":"Intra-individual stability of CSF biomarkers for Alzheimer\u2019s disease over two years","volume":"12","author":"Zetterberg","year":"2007","journal-title":"J. Alzheimer\u2019s Dis. JAD"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0304-3940(99)00617-5","article-title":"Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer\u2019s disease in patients with mild cognitive impairment","volume":"273","author":"Andreasen","year":"1999","journal-title":"Neurosci. Lett."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.3233\/JAD-140339","article-title":"Preclinical cerebrospinal fluid and volumetric magnetic resonance imaging biomarkers in Swedish familial Alzheimer\u2019s disease","volume":"43","author":"Thordardottir","year":"2015","journal-title":"J. Alzheimer\u2019s Dis. JAD"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa1202753","article-title":"Clinical and biomarker changes in dominantly inherited Alzheimer\u2019s disease","volume":"367","author":"Bateman","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S1474-4422(13)70194-7","article-title":"Preclinical Alzheimer\u2019s disease and its outcome: A longitudinal cohort study","volume":"12","author":"Vos","year":"2013","journal-title":"Lancet Neurol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1159\/000068478","article-title":"Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: A population-based study in 85-year-olds","volume":"15","author":"Skoog","year":"2003","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1136\/jnnp.2006.100529","article-title":"Cerebrospinal fluid beta-amyloid 1\u201342 concentration may predict cognitive decline in older women","volume":"78","author":"Gustafson","year":"2007","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000335729","article-title":"Cerebrospinal fluid biomarkers and proximity to diagnosis in preclinical familial Alzheimer\u2019s disease","volume":"33","author":"Ringman","year":"2012","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S1474-4422(14)70090-0","article-title":"Advancing research diagnostic criteria for Alzheimer\u2019s disease: The IWG-2 criteria","volume":"13","author":"Dubois","year":"2014","journal-title":"Lancet Neurol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1001\/archgenpsychiatry.2011.155","article-title":"Cerebrospinal fluid levels of beta-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia","volume":"69","author":"Buchhave","year":"2012","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/ana.21610","article-title":"Cerebrospinal fluid biomarker signature in Alzheimer\u2019s disease neuroimaging initiative subjects","volume":"65","author":"Shaw","year":"2009","journal-title":"Ann. Neurol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1474-4422(09)70139-5","article-title":"Prevalence and prognostic value of CSF markers of Alzheimer\u2019s disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: A prospective cohort study","volume":"8","author":"Visser","year":"2009","journal-title":"Lancet Neurol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Giau, V.V., Bagyinszky, E., and An, S.S.A. (2019). Potential Fluid Biomarkers for the Diagnosis of Mild Cognitive Impairment. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20174149"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/alzrt64","article-title":"Non-linear relationships of cerebrospinal fluid biomarker levels with cognitive function: An observational study","volume":"3","author":"Williams","year":"2011","journal-title":"Alzheimers Res. Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/acn3.274","article-title":"CSF Abeta42\/Abeta40 and Abeta42\/Abeta38 ratios: Better diagnostic markers of Alzheimer disease","volume":"3","author":"Janelidze","year":"2016","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13195-019-0485-0","article-title":"Advantages and disadvantages of the use of the CSF Amyloid beta (Abeta) 42\/40 ratio in the diagnosis of Alzheimer\u2019s Disease","volume":"11","author":"Hansson","year":"2019","journal-title":"Alzheimers Res. Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/cns.12476","article-title":"Cerebrospinal Fluid Abeta42 Levels: When Physiological Become Pathological State","volume":"21","author":"Martorana","year":"2015","journal-title":"CNS Neurosci. Ther."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0304-3940(01)02285-6","article-title":"Low cerebrospinal fluid beta-amyloid 42 in patients with acute bacterial meningitis and normalization after treatment","volume":"314","author":"Sjogren","year":"2001","journal-title":"Neurosci. Lett."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13024-017-0152-5","article-title":"Ex vivo (18)O-labeling mass spectrometry identifies a peripheral amyloid beta clearance pathway","volume":"12","author":"Portelius","year":"2017","journal-title":"Mol. Neurodegener."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1001\/archpsyc.61.1.95","article-title":"Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: A comparative cerebrospinal fluid study","volume":"61","author":"Hampel","year":"2004","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3233\/JAD-150167","article-title":"Greater specificity for cerebrospinal fluid P-tau231 over P-tau181 in the differentiation of healthy controls from Alzheimer\u2019s disease","volume":"49","author":"Spiegel","year":"2016","journal-title":"J. Alzheimer\u2019s Dis. JAD"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1001\/archneur.64.3.noc60123","article-title":"Cerebrospinal fluid tau\/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults","volume":"64","author":"Fagan","year":"2007","journal-title":"Arch. Neurol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1001\/archneur.60.9.1202","article-title":"Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to beta-amyloid peptide42","volume":"60","author":"Maddalena","year":"2003","journal-title":"Arch. Neurol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S1474-4422(03)00530-1","article-title":"CSF markers for incipient Alzheimer\u2019s disease","volume":"2","author":"Blennow","year":"2003","journal-title":"Lancet. Neurol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jalz.2014.02.004","article-title":"Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer\u2019s disease","volume":"11","author":"Blennow","year":"2015","journal-title":"Alzheimer\u2019s Dement. J. Alzheimer\u2019s Assoc."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0304-3940(00)01697-9","article-title":"Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke","volume":"297","author":"Hesse","year":"2001","journal-title":"Neurosci. Lett."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1001\/archneurol.2011.105","article-title":"Comparison of analytical platforms for cerebrospinal fluid measures of \u03b2-amyloid 1\u201342, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology","volume":"68","author":"Fagan","year":"2011","journal-title":"Arch. Neurol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1080\/15622970701535502","article-title":"Do CSF total tau, phosphorylated tau, and beta-amyloid 42 help to predict progression of mild cognitive impairment to Alzheimer\u2019s disease? A systematic review and meta-analysis of the literature","volume":"9","author":"Diniz","year":"2008","journal-title":"World J. Biol. Psychiatry Off. J. World Fed. Soc. Biol. Psychiatry"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S1474-4422(06)70355-6","article-title":"Association between CSF biomarkers and incipient Alzheimer\u2019s disease in patients with mild cognitive impairment: A follow-up study","volume":"5","author":"Hansson","year":"2006","journal-title":"Lancet Neurol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1159\/000090631","article-title":"CSF biomarkers for Alzheimer\u2019s Disease: Levels of beta-amyloid, tau, phosphorylated tau relate to clinical symptoms and survival","volume":"21","author":"Wallin","year":"2006","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1001\/jama.2009.1064","article-title":"CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment","volume":"302","author":"Mattsson","year":"2009","journal-title":"JAMA"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1177\/1533317513504615","article-title":"Cerebrospinal fluid biomarkers of Alzheimer\u2019s disease in Chinese patients: A pilot study","volume":"28","author":"Shea","year":"2013","journal-title":"Am. J. Alzheimer\u2019s Dis. Dement."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/WAD.0000000000000184","article-title":"Cerebrospinal Fluid Biomarkers for the Diagnosis of Alzheimer Disease in South Korea","volume":"31","author":"Park","year":"2017","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"745","DOI":"10.3233\/JAD-2011-110551","article-title":"Quantifying the Pathophysiological Timeline of Alzheimer\u2019s Disease","volume":"26","author":"Yang","year":"2011","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1001\/archneur.64.3.354","article-title":"Association of low plasma Abeta42\/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease","volume":"64","author":"Crook","year":"2007","journal-title":"Arch. Neurol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.neurobiolaging.2006.03.004","article-title":"Plasma levels of beta-amyloid (1-42) in Alzheimer\u2019s disease and mild cognitive impairment","volume":"27","author":"Pesaresi","year":"2006","journal-title":"Neurobiol. Aging"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S1474-4422(06)70501-4","article-title":"Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: A prospective case-cohort study","volume":"5","author":"Hofman","year":"2006","journal-title":"Lancet. Neurol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.bbrc.2012.06.017","article-title":"Plasma amyloid-\u03b2 oligomers level is a biomarker for Alzheimer\u2019s disease diagnosis","volume":"423","author":"Zhou","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"41","DOI":"10.12779\/dnd.2018.17.2.41","article-title":"Plasma Oligomeric Beta Amyloid in Alzheimer\u2019s Disease with History of Agent Orange Exposure","volume":"17","author":"Yang","year":"2018","journal-title":"Dement. Neurocogn Disord."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"236.e1","DOI":"10.1016\/j.neurobiolaging.2019.08.026","article-title":"Novel Amyloid Precursor Protein mutation, Val669Leu (\u201cSeoul APP\u201d), in a Korean Early onset Alzheimer\u2019s disease patient","volume":"84","author":"Bagyinszky","year":"2019","journal-title":"Neurobiol. Aging"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1212\/WNL.0b013e3181b78448","article-title":"Association of plasma amyloid beta with risk of dementia: The prospective Three-City Study","volume":"73","author":"Lambert","year":"2009","journal-title":"Neurology"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13195-017-0324-0","article-title":"Oligomeric forms of amyloid-\u03b2 protein in plasma as a potential blood-based biomarker for Alzheimer\u2019s disease","volume":"9","author":"Wang","year":"2017","journal-title":"Alzheimers Res. Ther."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13195-017-0310-6","article-title":"Dynamic changes of oligomeric amyloid \u03b2 levels in plasma induced by spiked synthetic A\u03b2(42)","volume":"9","author":"An","year":"2017","journal-title":"Alzheimers Res. Ther."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13195-019-0499-7","article-title":"Blood amyloid-\u03b2 oligomerization associated with neurodegeneration of Alzheimer\u2019s disease","volume":"11","author":"Youn","year":"2019","journal-title":"Alzheimers Res. Ther."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3233\/JAD-170402","article-title":"Intracranial Arterial 4D Flow in Individuals with Mild Cognitive Impairment is Associated with Cognitive Performance and Amyloid Positivity","volume":"60","author":"Berman","year":"2017","journal-title":"J. Alzheimer\u2019s Dis. JAD"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1177\/1756285612455367","article-title":"Neurochemical biomarkers in Alzheimer\u2019s disease and related disorders","volume":"5","author":"Bibl","year":"2012","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2217\/bmm-2017-0433","article-title":"Update on biomarkers for amyloid pathology in Alzheimer\u2019s disease","volume":"12","author":"Ashton","year":"2018","journal-title":"Biomark. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1002\/ana.25334","article-title":"Plasma Amyloid as Prescreener for the Earliest Alzheimer Pathological Changes","volume":"84","author":"Verberk","year":"2018","journal-title":"Ann. Neurol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"26801","DOI":"10.1038\/srep26801","article-title":"Plasma beta-amyloid in Alzheimer\u2019s disease and vascular disease","volume":"6","author":"Janelidze","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.3233\/JAD-170784","article-title":"Plasma Amyloid-beta (Abeta42) Correlates with Cerebrospinal Fluid Abeta42 in Alzheimer\u2019s Disease","volume":"62","author":"Teunissen","year":"2018","journal-title":"J. Alzheimer\u2019s Dis. JAD"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3389\/fnagi.2018.00175","article-title":"The Relation Between Brain Amyloid Deposition, Cortical Atrophy, and Plasma Biomarkers in Amnesic Mild Cognitive Impairment and Alzheimer\u2019s Disease","volume":"10","author":"Fan","year":"2018","journal-title":"Front. Aging Neurosci."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Zetterberg, H., M\u00f6rtberg, E., Song, L., Chang, L., Provuncher, G.K., Patel, P.P., Ferrell, E., Fournier, D.R., Kan, C.W., and Campbell, T.G. (2011). Hypoxia Due to Cardiac Arrest Induces a Time-Dependent Increase in Serum Amyloid \u03b2 Levels in Humans. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0028263"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e8763","DOI":"10.15252\/emmm.201708763","article-title":"Amyloid blood biomarker detects Alzheimer\u2019s disease","volume":"10","author":"Nabers","year":"2018","journal-title":"EMBO Mol. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3389\/fnagi.2017.00226","article-title":"Plasma Levels of Abeta42 and Tau Identified Probable Alzheimer\u2019s Dementia: Findings in Two Cohorts","volume":"9","author":"Lue","year":"2017","journal-title":"Front. Aging Neurosci."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0304-3940(95)11297-A","article-title":"Increased cerebrospinal fluid tau in patients with Alzheimer\u2019s disease","volume":"186","author":"Jensen","year":"1995","journal-title":"Neurosci. Lett."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1212\/WNL.0b013e3181dd4dd8","article-title":"CSF biomarkers predict a more malignant outcome in Alzheimer disease","volume":"74","author":"Wallin","year":"2010","journal-title":"Neurology"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3389\/fnagi.2017.00210","article-title":"Cerebrospinal Fluid Abeta43 Is Reduced in Early-Onset Compared to Late-Onset Alzheimer\u2019s Disease, But Has Similar Diagnostic Accuracy to Abeta42","volume":"9","author":"Lauridsen","year":"2017","journal-title":"Front. Aging Neurosci."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s00401-018-1948-2","article-title":"Novel tau fragments in cerebrospinal fluid: Relation to tangle pathology and cognitive decline in Alzheimer\u2019s disease","volume":"137","author":"Cicognola","year":"2019","journal-title":"Acta Neuropathol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/alzrt163","article-title":"Plasma tau levels in Alzheimer\u2019s disease","volume":"5","author":"Zetterberg","year":"2013","journal-title":"Alzheimers Res. Ther."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1001\/jamaneurol.2018.4666","article-title":"Assessment of Plasma Total Tau Level as a Predictive Biomarker for Dementia and Related Endophenotypes","volume":"76","author":"Pase","year":"2019","journal-title":"JAMA Neurol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jalz.2018.02.013","article-title":"Plasma phospho-tau181 increases with Alzheimer\u2019s disease clinical severity and is associated with tau- and amyloid-positron emission tomography","volume":"14","author":"Mielke","year":"2018","journal-title":"Alzheimer\u2019s Dement. J. Alzheimer\u2019s Assoc."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/s41591-020-0781-z","article-title":"A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer\u2019s disease","volume":"26","author":"Barthelemy","year":"2020","journal-title":"Nat. Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/ana.1054","article-title":"Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer\u2019s disease","volume":"50","author":"Itoh","year":"2001","journal-title":"Ann. Neurol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0304-3940(00)01178-2","article-title":"Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer\u2019s disease patients","volume":"287","author":"Kohnken","year":"2000","journal-title":"Neurosci. Lett."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1212\/WNL.59.4.627","article-title":"CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects","volume":"59","author":"Buerger","year":"2002","journal-title":"Neurology"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1373\/clinchem.2008.104497","article-title":"The brain injury biomarker VLP-1 is increased in the cerebrospinal fluid of Alzheimer disease patients","volume":"54","author":"Lee","year":"2008","journal-title":"Clin. Chem."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/sj.mp.4001379","article-title":"Neuronal expression of GFAP in patients with Alzheimer pathology and identification of novel GFAP splice forms","volume":"8","author":"Hol","year":"2003","journal-title":"Mol. Psychiatry"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.jns.2017.03.031","article-title":"Role of inflammatory molecules in the Alzheimer\u2019s disease progression and diagnosis","volume":"376","author":"Bagyinszky","year":"2017","journal-title":"J. Neurol. Sci."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"254","DOI":"10.3389\/fnagi.2019.00254","article-title":"Role of Neurofilament Light Chain as a Potential Biomarker for Alzheimer\u2019s Disease: A Correlative Meta-Analysis","volume":"11","author":"Jin","year":"2019","journal-title":"Front. Aging Neurosci."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/BF02815094","article-title":"Synaptotagmin, a synaptic vesicle protein, is present in human cerebrospinal fluid: A new biochemical marker for synaptic pathology in Alzheimer disease?","volume":"27","author":"Davidsson","year":"1996","journal-title":"Mol. Chem. Neuropathol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.brainres.2010.09.073","article-title":"Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer\u2019s disease","volume":"1362","author":"Thorsell","year":"2010","journal-title":"Brain Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/brain\/awx352","article-title":"Synaptic markers of cognitive decline in neurodegenerative diseases: A proteomic approach","volume":"141","author":"Bereczki","year":"2018","journal-title":"Brain A J. Neurol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.jalz.2016.04.005","article-title":"Synaptic proteins predict cognitive decline in Alzheimer\u2019s disease and Lewy body dementia","volume":"12","author":"Bereczki","year":"2016","journal-title":"Alzheimer\u2019s Dement. J. Alzheimer\u2019s Assoc."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jalz.2018.08.006","article-title":"Elevated CSF GAP-43 is Alzheimer\u2019s disease specific and associated with tau and amyloid pathology","volume":"15","author":"Sandelius","year":"2019","journal-title":"Alzheimer\u2019s Dement. J. Alzheimer\u2019s Assoc."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/1750-1326-9-53","article-title":"SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer\u2019s disease","volume":"9","author":"Brinkmalm","year":"2014","journal-title":"Mol. Neurodegener."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1007\/s13206-015-9306-8","article-title":"Optimization of specific multiplex DNA primers to detect variable CLU genomic lesions in patients with Alzheimer\u2019s disease","volume":"9","author":"An","year":"2015","journal-title":"BioChip J."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"164","DOI":"10.3389\/fnins.2019.00164","article-title":"Clusterin in Alzheimer\u2019s Disease: Mechanisms, Genetics, and Lessons From Other Pathologies","volume":"13","author":"Foster","year":"2019","journal-title":"Front. Neurosci."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"555","DOI":"10.2217\/clp.10.37","article-title":"Apolipoproteins in the brain: Implications for neurological and psychiatric disorders","volume":"51","author":"Elliott","year":"2010","journal-title":"Clin. Lipidol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2147\/NDT.S224877","article-title":"Association of Clusterin Levels in Cerebrospinal Fluid with Synaptic Degeneration Across the Alzheimer\u2019s Disease Continuum","volume":"16","author":"Wang","year":"2020","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13195-017-0319-x","article-title":"The clinical significance of plasma clusterin and A\u03b2 in the longitudinal follow-up of patients with Alzheimer\u2019s disease","volume":"9","author":"Hsu","year":"2017","journal-title":"Alzheimers Res. Ther."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Silajdzic, E., Minthon, L., Bjorkqvist, M., and Hansson, O. (2012). No diagnostic value of plasma clusterin in Alzheimer\u2019s disease. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0050237"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3233\/JAD-2010-100819","article-title":"Ocular biomarkers for early detection of Alzheimer\u2019s disease","volume":"22","author":"Frost","year":"2010","journal-title":"J. Alzheimer\u2019s Dis. JAD"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"e233","DOI":"10.1038\/tp.2012.150","article-title":"Retinal vascular biomarkers for early detection and monitoring of Alzheimer\u2019s disease","volume":"3","author":"Frost","year":"2013","journal-title":"Transl. Psychiatry"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.3233\/JAD-180622","article-title":"Abeta42\/Abeta40 and Abeta42\/Abeta38 Ratios Are Associated with Measures of Gait Variability and Activities of Daily Living in Mild Alzheimer\u2019s Disease: A Pilot Study","volume":"65","author":"Koychev","year":"2018","journal-title":"J. Alzheimer\u2019s Dis. JAD"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1159\/000335154","article-title":"Alzheimer\u2019s disease in the retina: Imaging retinal abeta plaques for early diagnosis and therapy assessment","volume":"10","author":"Koronyo","year":"2012","journal-title":"Neuro-Degener. Dis."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/ana.24548","article-title":"Melanopsin retinal ganglion cell loss in Alzheimer disease","volume":"79","author":"Morgia","year":"2016","journal-title":"Ann. Neurol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"S204","DOI":"10.1016\/j.neuroimage.2010.06.020","article-title":"Identification of amyloid plaques in retinas from Alzheimer\u2019s patients and noninvasive in vivo optical imaging of retinal plaques in a mouse model","volume":"54","author":"Koronyo","year":"2011","journal-title":"NeuroImage"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1007\/s00417-009-1060-3","article-title":"Amyloid precursor protein processing and retinal pathology in mouse models of Alzheimer\u2019s disease","volume":"247","author":"Dutescu","year":"2009","journal-title":"Graefe\u2019s Arch. Clin. Exp. Ophthalmol. Albrecht von Graefes Arch. fur Klin. und Exp. Ophthalmol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"10169","DOI":"10.1074\/jbc.271.17.10169","article-title":"Oxidative stress increases production of beta-amyloid precursor protein and beta-amyloid (Abeta) in mammalian lenses, and Abeta has toxic effects on lens epithelial cells","volume":"271","author":"Frederikse","year":"1996","journal-title":"J. Biol. Chem."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0140-6736(03)12981-9","article-title":"Cytosolic beta-amyloid deposition and supranuclear cataracts in lenses from people with Alzheimer\u2019s disease","volume":"361","author":"Goldstein","year":"2003","journal-title":"Lancet (London, England)"},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Moncaster, J.A., Pineda, R., Moir, R.D., Lu, S., Burton, M.A., Ghosh, J.G., Ericsson, M., Soscia, S.J., Mocofanescu, A., and Folkerth, R.D. (2010). Alzheimer\u2019s disease amyloid-beta links lens and brain pathology in Down syndrome. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0010659"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.neulet.2016.04.059","article-title":"Amyloid beta accumulation and inner retinal degenerative changes in Alzheimer\u2019s disease transgenic mouse","volume":"623","author":"Gupta","year":"2016","journal-title":"Neurosci. Lett."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/ceo.12872","article-title":"Emerging ocular biomarkers of Alzheimer disease","volume":"45","author":"Hadoux","year":"2017","journal-title":"Clin. Exp. Ophthalmol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jns.2015.12.005","article-title":"Emergence of exosomal miRNAs as a diagnostic biomarker for Alzheimer\u2019s disease","volume":"360","author":"An","year":"2016","journal-title":"J. Neurol. Sci."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"28","DOI":"10.5483\/BMBRep.2020.53.1.278","article-title":"Sphingolipids in neuroinflammation: A potential target for diagnosis and therapy","volume":"53","author":"Lee","year":"2020","journal-title":"BMB Rep."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Mil\u00e0-Alom\u00e0, M., Su\u00e1rez-Calvet, M., and Molinuevo, J.L. (2019). Latest advances in cerebrospinal fluid and blood biomarkers of Alzheimer\u2019s disease. Ther. Adv. Neurol. Disord.","DOI":"10.1177\/1756286419888819"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.nbd.2018.02.014","article-title":"Neuronal pentraxin 1: A synaptic-derived plasma biomarker in Alzheimer\u2019s disease","volume":"114","author":"Ma","year":"2018","journal-title":"Neurobiol. Dis."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s11357-019-00127-6","article-title":"Serum beta-secretase 1 (BACE1) activity as candidate biomarker for late-onset Alzheimer\u2019s disease","volume":"42","author":"Cervellati","year":"2020","journal-title":"GeroScience"},{"key":"ref_129","first-page":"166","article-title":"Identification of blood-based biomarkers","volume":"17","author":"Crunkhorn","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.2147\/NDT.S84266","article-title":"Role of apolipoprotein E in neurodegenerative diseases","volume":"11","author":"Giau","year":"2015","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.3389\/fneur.2019.01036","article-title":"Albumin Exchange in Alzheimer\u2019s Disease: Might CSF Be an Alternative Route to Plasma?","volume":"10","author":"Gasparovic","year":"2019","journal-title":"Front. Neurol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13024-019-0320-x","article-title":"\u03b1-synuclein in the pathophysiology of Alzheimer\u2019s disease","volume":"14","author":"Twohig","year":"2019","journal-title":"Mol. Neurodegener."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"e12801","DOI":"10.1111\/acel.12801","article-title":"The emerging roles of protein homeostasis-governing pathways in Alzheimer\u2019s disease","volume":"17","author":"Cheng","year":"2018","journal-title":"Aging Cell"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1146\/annurev-biochem-060614-033955","article-title":"The biology of proteostasis in aging and disease","volume":"84","author":"Labbadia","year":"2015","journal-title":"Annu. Rev. Biochem."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/ana.22448","article-title":"Visinin-like protein-1: Diagnostic and prognostic biomarker in Alzheimer disease","volume":"70","author":"Tarawneh","year":"2011","journal-title":"Ann. Neurol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.jalz.2018.12.019","article-title":"Emerging cerebrospinal fluid biomarkers in autosomal dominant Alzheimer\u2019s disease","volume":"15","author":"Schindler","year":"2019","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/ana.22628","article-title":"An operational approach to National Institute on Aging-Alzheimer\u2019s Association criteria for preclinical Alzheimer disease","volume":"71","author":"Jack","year":"2012","journal-title":"Ann. Neurol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.arr.2017.02.003","article-title":"Suspected non-Alzheimer\u2019s pathology - Is it non-Alzheimer\u2019s or non-amyloid?","volume":"36","author":"Dani","year":"2017","journal-title":"Ageing Res. Rev."}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/10\/5\/326\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:30:50Z","timestamp":1760175050000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/10\/5\/326"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,20]]},"references-count":138,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,5]]}},"alternative-id":["diagnostics10050326"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics10050326","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,20]]}}}